GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
The partners will offer pharmaceutical firms a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests.
